Form 4: Medtronic EVP Sean Salmon Reports Acquisition of Shares and Derivative Securities

EVP & President Cardiovascular of Medtronic, Sean Salmon, reports acquiring shares and derivative securities, including performance share units and stock options.

Summary

• Sean Salmon, EVP & President Cardiovascular at Medtronic, filed a Form 4 detailing changes in beneficial ownership.
• On July 29, 2024, Salmon acquired 14,375 ordinary shares.
• Salmon also acquired 35,938 performance share units that vest on July 29, 2027.
• The number of shares issued for the PSUs will depend on performance metrics over a three-year period, potentially ranging from 0 to 71,876 shares.
• Additionally, Salmon acquired options to buy 106,260 ordinary shares at a price of $80, exercisable at a rate of 25% per year starting on the first anniversary of the grant.
• Salmon's total beneficially owned ordinary shares after the transaction is 63,084.
• Salmon's total beneficially owned performance share units after the transaction is 35,938.
• Salmon's total beneficially owned stock options after the transaction is 106,260.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing related to executive compensation. The acquisition of shares and derivative securities could be seen as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of shares and performance share units by a high-ranking executive could be interpreted as a positive signal about the company's future prospects.
• The vesting of performance share units is tied to performance metrics, aligning executive compensation with company goals.

Future Outlook

The number of shares to be issued in connection with the performance share units will vary depending on the level of certain performance metrics achieved over a three (3) year performance period.

Industry Context

Executive stock ownership is common in the medical device industry to align management interests with shareholder value. This filing reflects standard practices for incentivizing executives at Medtronic.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include a mix of salary, stock options, and performance-based equity awards.
• Companies like Abbott, Boston Scientific, and Stryker also utilize performance share units and stock options to incentivize their executives.
• The vesting schedules and performance metrics associated with these awards are typically aligned with long-term strategic goals and shareholder value creation.

Stakeholder Impact

• The acquisition of shares by an executive could positively influence shareholder confidence.
• The performance-based nature of the share units aligns executive interests with those of the shareholders.

Key Dates